Xeris Biopharma Holdings, Inc.XERSNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +12.31% | +35.39% | +47.94% | +48.84% | +37.06% |
| Gross Profit Growth | +1.39% | +48.41% | +48.24% | +51.55% | +55.83% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +7.92% | +7.94% | +8.49% | +5.14% | +19.21% |
| Weighted Average Shares Diluted Growth | +7.92% | +7.94% | +8.49% | +5.14% | +19.21% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | -68.58% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | -71.48% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -10.50% | +3.11% | +23.83% | +25.00% | +30.66% |
| Inventory Growth | +18.29% | +24.04% | +28.90% | +56.55% | +49.52% |
| Asset Growth | -2.04% | +0.14% | -6.29% | +0.89% | +15.29% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +18.87% | +18.44% | +0.02% | -4.66% | -85.91% |
| R&D Expense Growth | +16.96% | -4.54% | -0.87% | +39.87% | +27.09% |
| SG&A Expenses Growth | +20.60% | +6.84% | +14.69% | +11.00% | +3.31% |